Presented by: Anna Podolanczuk, MD, MS and Sandeep Bansal, MD, FCCP, FACP

An accurate Interstitial Lung Disease (ILD) diagnosis is important to guide prognosis and treatment. ILD is frequently challenging to diagnose particularly when a clear answer is not available on high resolution CT. In this webinar, speakers will discuss updated IPF/PPF guidelines, key utility data, and the role of the Envisia Genomic Classifier in the diagnosis and prognosis of ILD. New data will be presented that demonstrates how the Envisia Classifier can predict clinical progression in fibrotic ILD.

An Envisia positive result may serve as a biomarker for FVC by identifying the genomic signature of UIP in patients without definite UIP on CT.  Results for the study showed that patients with an Envisia positive result show a greater decline in FVC over time compared to Envisia negative patients​.

These findings show that an Envisia positive result may help identify patients in whom two-drug immunosuppressive therapy is harmful. These results further support the utility of Envisia, highlighting the potential of an Envisia positive result to inform both diagnosis and treatment decisions, identifying patients in whom antifibrotic therapy may be preferred.

Presented by: Fayez Kheir, MD & Mary Beth Scholand, MD.

In this webinar speakers review published data on the Envisia Genomic Classifier, updates from the recent IPF/PPF clinical guideline, and how they have integrated the classifier into their practice.